Purple Biotech (STU:1YI0) Accounts Payable: €0.42 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1YI0 Purple Biotech Ltd STU:1YI0
10 GF Score
Price €63.20
! 2 Warning Signs
View Full Analysis

What is Purple Biotech Accounts Payable?

Purple Biotech STU:1YI0 10 Accounts Payable is €0.42 Mil as of Jun. 2026. GuruFocus rates STU:1YI0 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Purple Biotech's Accounts Payable for the quarter that ended in Jun. 2026 was €0.42 Mil.

Purple Biotech's quarterly Accounts Payable declined from Dec. 2025 (€1.77 Mil) to Mar. 2026 (€0.73 Mil) and declined from Mar. 2026 (€0.73 Mil) to Jun. 2026 (€0.42 Mil).

Purple Biotech's annual Accounts Payable declined from Dec. 2023 (€3.24 Mil) to Dec. 2024 (€1.39 Mil) but then increased from Dec. 2024 (€1.39 Mil) to Dec. 2025 (€1.77 Mil).

Purple Biotech Accounts Payable Related Terms

Purple Biotech Accounts Payable Historical Data

* Premium members only.

The historical data trend for Purple Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Purple Biotech Accounts Payable Chart

Purple Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.30 2.01 3.24 1.39 1.77

Purple Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.52 1.77 0.73 0.42
STU:1YI0
10GF Score
Purple Biotech Ltd STU:1YI0
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Purple Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €0.42 Mil mean?
Purple Biotech (STU:1YI0) has a Accounts Payable of €0.42 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Purple Biotech and its competitors.
Is Purple Biotech's Accounts Payable too high?
Purple Biotech's current Accounts Payable is €0.42 Mil. Overall, Purple Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Purple Biotech's Accounts Payable compare to VRTX and REGN?
Purple Biotech's Accounts Payable of €0.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Purple Biotech and its competitors. Purple Biotech's current Accounts Payable is €0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Purple Biotech stock overvalued right now?
Purple Biotech (STU:1YI0) has a current Accounts Payable of €0.42 Mil. The current Accounts Payable is €0.42 Mil. Purple Biotech's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Purple Biotech (STU:1YI0), the current Accounts Payable is €0.42 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Purple Biotech Business Description

Other Exchanges PPBT:USAPPBT:Israel
Address 4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
10GF Score

Get the complete analysis for STU:1YI0

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.20
Price